Apstatin (TFA)

• Description:

  Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection[1][2].

• UNSPSC:

  12352211

• Target:

  Aminopeptidase

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Purity:

  99.43

• Smiles:

  C[C@@H](C(N)=O)NC([C@H]1N(C([C@H]2N(C([C@@H](O)[C@H](N)CC3=CC=CC=C3)=O)CCC2)=O)CCC1)=O.O=C(O)C(F)(F)F

• Molecular Formula:

  C25H34F3N5O7

• Molecular Weight:

  573.56

• References & Citations:

  [1]Wolfrum S, et al. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol. 2001 Sep;134 (2) :370-4. |[2]Maggiora LL, et al. Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42 (13) :2394-402.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported